|
May 1
|
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
|
|
May 1
|
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
|
|
Apr 19
|
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
|
|
Apr 17
|
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
|
|
Apr 4
|
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
|
Dec 8
|
G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%
|
|
Dec 5
|
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
|
|
Dec 1
|
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 30
|
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
|
|
Nov 11
|
When Will G1 Therapeutics, Inc. (NASDAQ:GTHX) Turn A Profit?
|
|
Nov 2
|
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript
|